AptaPrecision: Personalized screening for minimal residual disease in multiple myeloma

Unmet Medical Need: Minimal residual disease (MRD) is the major cause for relapse of blood cancers such as multiple myeloma (MM), acute and chronic lymphoid leukemias, and acute myeloid leukemia. However, current methods for MRD detection in MM depend on invasive, failure-prone bone marrow aspiration procedures, and therefore do not offer sufficient timeliness and reliability. 

Envisioned Healthcare Product: The AptaPrecision team has created a method for noninvasive detection of tumor load, thus allowing timely and reliable MRD detection in order to improve screening results and treatment outcomes, while also reducing screening costs.  

Stage of Development:  Validation

December 2015 Precision Medicine Pilot AWARD

February 2017 AWARD from the NCI and NIH 

2017 Article

Collaborative Research Team:  Qiao Lin, PhD and Tilla Worgall, MD, PhD 


Funding Cycle: 2016-2017